{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Urachal+Adenocarcinoma",
    "query": {
      "condition": "Urachal Adenocarcinoma"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 4,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-10T18:05:52.285Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04923178",
      "title": "A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Urothelial Cancer",
        "Bladder Cancer",
        "Genitourinary Cancer",
        "Urogenital Neoplasms",
        "Urogenital Cancer"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1100,
      "start_date": "2022-10-24",
      "completion_date": "2042-12-01",
      "has_results": false,
      "last_update_posted_date": "2026-06-05",
      "last_synced_at": "2026-06-10T18:05:52.285Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04923178"
    },
    {
      "nct_id": "NCT05756569",
      "title": "Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bladder Squamous Cell Carcinoma",
        "Locally Advanced Bladder Carcinoma",
        "Malignant Renal Pelvis Neoplasm",
        "Malignant Ureter Neoplasm",
        "Malignant Urethral Neoplasm",
        "Metastatic Bladder Carcinoma",
        "Stage III Bladder Cancer AJCC v8",
        "Stage IV Bladder Cancer AJCC v8",
        "Unresectable Bladder Carcinoma",
        "Urachal Adenocarcinoma",
        "Bladder Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Enfortumab Vedotin",
          "type": "DRUG"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2023-09-26",
      "completion_date": "2027-12-16",
      "has_results": false,
      "last_update_posted_date": "2025-07-28",
      "last_synced_at": "2026-06-10T18:05:52.285Z",
      "location_count": 4,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05756569"
    },
    {
      "nct_id": "NCT00082706",
      "title": "Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bladder Cancer",
        "Urethral Cancer",
        "Urachal Cancer"
      ],
      "interventions": [
        {
          "name": "5-Fluorouracil (5-FU)",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 46,
      "start_date": "2003-04-23",
      "completion_date": "2025-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-09-09",
      "last_synced_at": "2026-06-10T18:05:52.285Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00082706"
    },
    {
      "nct_id": "NCT03866382",
      "title": "Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bladder Adenocarcinoma",
        "Bladder Clear Cell Adenocarcinoma",
        "Bladder Mixed Adenocarcinoma",
        "Bladder Neuroendocrine Carcinoma",
        "Bladder Small Cell Neuroendocrine Carcinoma",
        "Bladder Squamous Cell Carcinoma",
        "Chromophobe Renal Cell Carcinoma",
        "Collecting Duct Carcinoma",
        "Invasive Bladder Giant Cell Urothelial Carcinoma",
        "Invasive Bladder Lymphoepithelioma-Like Carcinoma",
        "Invasive Bladder Nested Urothelial Carcinoma",
        "Invasive Bladder Plasmacytoid Urothelial Carcinoma",
        "Invasive Bladder Sarcomatoid Urothelial Carcinoma",
        "Invasive Bladder Urothelial Carcinoma",
        "Kidney Medullary Carcinoma",
        "Large Cell Neuroendocrine Carcinoma",
        "Malignant Testicular Leydig Cell Tumor",
        "Malignant Testicular Sertoli Cell Tumor",
        "Metastatic Bladder Carcinoma",
        "Metastatic Bladder Clear Cell (Glycogen-Rich) Urothelial Carcinoma",
        "Metastatic Bladder Giant Cell Urothelial Carcinoma",
        "Metastatic Bladder Large Cell Neuroendocrine Carcinoma",
        "Metastatic Bladder Lipid-Rich Urothelial Carcinoma",
        "Metastatic Bladder Micropapillary Urothelial Carcinoma",
        "Metastatic Bladder Plasmacytoid Urothelial Carcinoma",
        "Metastatic Bladder Sarcomatoid Urothelial Carcinoma",
        "Metastatic Bladder Small Cell Neuroendocrine Carcinoma",
        "Metastatic Bladder Squamous Cell Carcinoma",
        "Metastatic Chromophobe Renal Cell Carcinoma",
        "Metastatic Kidney Medullary Carcinoma",
        "Metastatic Malignant Genitourinary System Neoplasm",
        "Metastatic Papillary Renal Cell Carcinoma",
        "Metastatic Penile Carcinoma",
        "Metastatic Prostate Small Cell Neuroendocrine Carcinoma",
        "Metastatic Sarcomatoid Renal Cell Carcinoma",
        "Metastatic Urethral Carcinoma",
        "Papillary Renal Cell Carcinoma",
        "Sarcomatoid Renal Cell Carcinoma",
        "Stage IV Bladder Cancer AJCC v8",
        "Stage IV Penile Cancer AJCC v8",
        "Stage IV Renal Cell Cancer AJCC v8",
        "Stage IV Urethral Cancer AJCC v8",
        "Stage IVB Prostate Cancer AJCC v8",
        "Urachal Adenocarcinoma",
        "Urethral Clear Cell Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Cabozantinib S-malate",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Echocardiography Test",
          "type": "PROCEDURE"
        },
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 314,
      "start_date": "2019-05-13",
      "completion_date": "2027-02-28",
      "has_results": false,
      "last_update_posted_date": "2026-06-03",
      "last_synced_at": "2026-06-10T18:05:52.285Z",
      "location_count": 578,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Kingman, Arizona + 376 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03866382"
    }
  ]
}